HPV vaccine manufacturers commit to supply vaccine for 84 million girls


  • Heather Mason
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Manufacturers of human papilloma virus (HPV) vaccines MSD, GSK, Innovax, Serum Institute of India and Walvax, have pledged to ramp up supply of the vaccine for countries supported by the vaccine alliance, Gavi.

Cervical cancer is the second most common form of cancer in women living in low- and middle-income countries and accounts for 85 per cent of the global cervical cancer cases.

Gavi has helped 30 countries to introduce HPV vaccine demonstration programmes, and 19 have been successfully introduced. This HPV vaccine commitment is part of an ongoing UNICEF-led tender that aims to enable Gavi to reach 84 million girls during the next five-year period, estimating the prevention of 1.4 million future deaths from cervical cancer.

Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance said, “HPV is one of the most impactful vaccines in the Gavi portfolio, and country demand is currently far in excess of supply. [This] commitment has the potential to save more lives, and to take significant steps towards our common goal of a world free of cervical cancer.”

The Global Vaccine Summit 2020 is being live-streamed today (4 June 2020).